Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corcept Therapeutics

74.45
-4.9200-6.20%
Post-market: 74.42-0.0300-0.04%19:38 EDT
Volume:2.54M
Turnover:189.32M
Market Cap:7.85B
PE:60.53
High:78.00
Open:77.60
Low:72.59
Close:79.37
Loading ...

Corcept Therapeutics price target raised to $128 from $78 at Piper Sandler

TIPRANKS
·
31 Mar

Truist Securities Adjusts Corcept Therapeutics Price Target to $150 From $76, Maintains Buy Rating

MT Newswires Live
·
31 Mar

BUZZ-Corcept hits record high as ovarian cancer drug succeeds late-stage trial

Reuters
·
31 Mar

Corcept Therapeutics Inc : Truist Securities Raises Target Price to $150 From $76

THOMSON REUTERS
·
31 Mar

HC Wainwright Adjusts Price Target on Corcept Therapeutics to $150 From $115, Maintains Buy Rating

MT Newswires Live
·
31 Mar

Corcept Therapeutics price target raised to $150 from $115 at H.C. Wainwright

TIPRANKS
·
31 Mar

Corcept Therapeutics Inc. : H.c. Wainwright Raises Target Price to $150 From $115

THOMSON REUTERS
·
31 Mar

Corcept Soars as Ovarian Cancer Drug Succeeds Late-Stage Trial

Reuters
·
31 Mar

Corcept Therapeutics Jumps 84% After Co's Ovarian Cancer Combo Drug Meets Main Goal in Late-Stage Study

THOMSON REUTERS
·
31 Mar

Sector Update: Health Care

MT Newswires Live
·
31 Mar

Corcept Therapeutics Shares Soar on Positive Ovarian Cancer Treatment Trial Results

Dow Jones
·
31 Mar

Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump

MT Newswires Live
·
31 Mar

Corcept Therapeutics Jumps 83% Premarket After Co's Ovarian Cancer Combination Drug Meets Main Goal in Late-Stage Study

THOMSON REUTERS
·
31 Mar

Corcept Therapeutics Says Primary Endpoint Met in Phase 3 Ovarian Cancer Drug Study; Shares Up Pre-Bell

MT Newswires Live
·
31 Mar

Corcept's ovarian cancer combination drug meets main goal in late-stage study

Reuters
·
31 Mar

Primary Endpoint Met in Corcept’s Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
31 Mar

Corcept Therapeutics Inc - Relaorilant Plus Nab-Paclitaxel Improves Survival Without Increasing Side Effects

THOMSON REUTERS
·
31 Mar

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Business Wire
·
31 Mar

Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?

Zacks
·
28 Mar

Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus

Zacks
·
28 Mar